Table 2:
Celecoxib group | Etoricoxib group | Control group | |||||||
---|---|---|---|---|---|---|---|---|---|
1st visit Median (IQR) | 2nd visit Median (IQR) | p | 1st visit Median (IQR) | 2nd visit Median (IQR) | p | 1st visit Median (IQR) | 2nd visit Median (IQR) | p | |
IL1β S | 0.24 (0.56) | 0.15 (0.12) | NS | 0.45 (0.51) | 0.23 (0.18) | 0.045 | 0.19 (0.19) | 0.21 (0.31) | NS |
IL1β JF | 0.65 (0.92) | 0.20 (0.62) | NS | 2.30 (5.77) | 1.60 (5.85) | NS | 0.40 (0.43) | 0.54 (0.88) | 0.001 |
IL1Ra S | 240.0 (180.0) | 250.0 (110.0) | NS | 250.0 (195.0) | 230.0 (295.0) | NS | 460.0 (740.0) | 710.0 (940.0) | NS |
IL1Ra JF | 340.0 (2210.0) | 460.0 (5000.0) | <0.001 | 460.0 (8210.0) | 1100.0 (8600.0) | NS | 450.0 (1475.0) | 400.0 (1095.0) | NS |
IL6 S | 1.30 (2.34) | 1.20 (1.67) | 0.003 | 1.70 (9.38) | 1.35 (9.55) | NS | 1.65 (1.10) | 1.60 (1.80) | NS |
IL6 JF | 500.0 (5010.0) | 420.0 (2065.0) | 0.017 | 1450.0 (11360.0) | 880.0 (3140.0) | 0.019 | 300.0 (1300.0) | 300.0 (1340.0) | NS |
TNF-α S | 1.20 (0.60) | 1.10 (0.40) | NS | 1.70 (1.00) | 1.10 (1.40) | NS | 1.30 (0.40) | 1.30 (0.35) | NS |
TNF-α JF | 1.50 (2.89) | 1.00 (3.10) | NS | 2.90 (5.15) | 1.40 (3.70) | NS | 1.10 (1.25) | 1.70 (2.80) | 0.01 |
sTNFR1 S | 1650.0 (500.0) | 1450.0 (450.0) | NS | 2000.0 (1200.0) | 1650.0 (1350.0) | NS | 1550.0 (1300.0) | 1450.0 (750.0) | NS |
sTNFR1 JF | 5000.0 (4500.0) | 7200.0 (4000.0) | NS | 7200.0 (5600.0) | 8400.0 (4600.0) | NS | 7200.0 (7300.0) | 5600.0 (6300.0) | NS |
sTNFR2 S | 3000.0 (600.0) | 2800.0 (500.0) | NS | 3300.0 (1000.0) | 2800.0 (600.0) | NS | 3400.0 (2800.0) | 3300.0 (2950.0) | NS |
sTNFR2 JF | 3500.0 (4400.0) | 4250.0 (3400.0) | NS | 4200.0 (5800.0) | 5750.0 (9000.0) | 0.017 | 4800.0 (5450.0) | 3600.0 (4200.0) | NS |
NS: non significant, IQR: interquartile range, s: soluble, S: serum, JF: joint fluid